<DOC>
	<DOCNO>NCT01072968</DOCNO>
	<brief_summary>Multicenter randomize double blind study versus placebo 12 week first , escalate dose period follow stable dose period select dose . This double-blind period follow 9 month open-label period patient wish continue study product .</brief_summary>
	<brief_title>BF2.649 Patients With OSA , Still Complaining EDS Refusing Treated CPAP .</brief_title>
	<detailed_description>The first period ( 12 week double blind period ) aim demonstrate efficacy safety BF2.649 verify whether result BF2.649 superior placebo . The aim second period ( open label extension phase ) ass long-term tolerance , well maintenance BF2.649 efficacy .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>Patients OSA still complain EDS , refuse nCPAP ESS score â‰¥ 12 Patients suffer insomnia without OSA Coexisting narcolepsy Patient sleep debt due OSA Acute chronic severe disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Multicenter</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Efficacy safety study</keyword>
	<keyword>BF2.649 versus placebo</keyword>
	<keyword>Patients suffer Obstructive Sleep Apnea</keyword>
	<keyword>Complaining Excessive Daytime Sleepiness</keyword>
	<keyword>Refusing nasal Continuous Positive Airway Pressure</keyword>
</DOC>